Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to 0.15%.

  • Aytu Biopharma's Return on Capital Employed fell 100.0% to 0.15% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.15%, marking a year-over-year decrease of 100.0%. This contributed to the annual value of 0.13% for FY2025, which is 1000.0% down from last year.
  • Latest data reveals that Aytu Biopharma reported Return on Capital Employed of 0.15% as of Q4 2025, which was down 100.0% from 0.14% recorded in Q3 2025.
  • Aytu Biopharma's Return on Capital Employed's 5-year high stood at 0.02% during Q1 2024, with a 5-year trough of 1.23% in Q2 2022.
  • For the 5-year period, Aytu Biopharma's Return on Capital Employed averaged around 0.41%, with its median value being 0.23% (2023).
  • As far as peak fluctuations go, Aytu Biopharma's Return on Capital Employed tumbled by -8600bps in 2022, and later soared by 10000bps in 2023.
  • Over the past 5 years, Aytu Biopharma's Return on Capital Employed (Quarter) stood at 0.71% in 2021, then crashed by -42bps to 1.01% in 2022, then soared by 91bps to 0.09% in 2023, then tumbled by -51bps to 0.14% in 2024, then fell by -10bps to 0.15% in 2025.
  • Its Return on Capital Employed stands at 0.15% for Q4 2025, versus 0.14% for Q3 2025 and 0.13% for Q2 2025.